The Vaccination Concerns in COVID-19 Scale (VaCCS) : Development and validation
Hamilton, K., & Hagger, M. S. (2022). The Vaccination Concerns in COVID-19 Scale (VaCCS) : Development and validation. PLoS ONE, 17(3), Article e0264784. https://doi.org/10.1371/journal.pone.0264784
Published inPLoS ONE
© 2022 the Authors
Vaccines are highly effective in minimizing serious cases of COVID-19 and pivotal to managing the COVID-19 pandemic. Despite widespread availability, vaccination rates fall short of levels required to bring about widespread immunity, with low rates attributed to vaccine hesitancy. It is therefore important to identify the beliefs and concerns associated with vaccine intentions and uptake. The present study aimed to develop and validate, using the AMEE Guide, the Vaccination Concerns in COVID-19 Scale (VaCCS), a comprehensive measure of beliefs and concerns with respect to COVID-19 vaccines. In the scale development phase, samples of Australian (N = 53) and USA (N = 48) residents completed an initial open-response survey to elicit beliefs and concerns about COVID-19 vaccines. A concurrent rapid literature review was conducted to identify content from existing scales on vaccination beliefs. An initial pool of items was developed informed by the survey responses and rapid review. The readability and face validity of the item pool was assessed by behavioral science experts (N = 5) and non-experts (N = 10). In the scale validation phase, samples of Australian (N = 522) and USA (N = 499) residents completed scaled versions of the final item pool and measures of socio-political, health beliefs and outcomes, and trait measures. Exploratory factor analysis yielded a scale comprising 35 items with 8 subscales, and subsequent confirmatory factor analyses indicated acceptable fit of the scale structure with the data in each sample and factorial invariance across samples. Concurrent and predictive validity tests indicated a theoretically and conceptually predictable pattern of relations between the VaCCS subscales with the socio-political, health beliefs and outcomes, and trait measures, and key subscales predicted intentions to receive the COVID-19 vaccine. The VaCCS provides a novel measure to assess beliefs and concerns toward COVID-19 vaccination that researchers and practitioners can use in its entirety or select specific sub-scales to use according to their needs. ...
PublisherPublic Library of Science (PLoS)
ISSN Search the Publication Forum1932-6203
Dataset(s) related to the publicationhttps://osf.io/k96bn/
Publication in research information system
MetadataShow full item record
- Liikuntatieteiden tiedekunta 
Additional information about fundingThe author(s) received no specific funding for this work.
Showing items with similar title or keywords.
Predicting COVID‐19 booster vaccine intentions Hagger, Martin S.; Hamilton, Kyra (Wiley-Blackwell, 2022)Achieving broad immunity through vaccination is a cornerstone strategy for long-term management of COVID-19 infections, particularly the prevention of serious cases and hospitalizations. Evidence that vaccine-induced ...
Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine Hankaniemi, Minna M.; Baikoghli, Mo A.; Stone, Virginia M.; Xing, Li; Väätäinen, Outi; Soppela, Saana; Sioofy-Khojine, Amirbabak; Saarinen, Niila V. V.; Ou, Tingwei; Anson, Brandon; Hyöty, Heikki; Marjomäki, Varpu; Flodström-Tullberg, Malin; Cheng, R. H.; Hytönen, Vesa P.; Laitinen, Olli H. (MDPI, 2020)Coxsackievirus B (CVB) enteroviruses are common pathogens that can cause acute and chronic myocarditis, dilated cardiomyopathy, aseptic meningitis, and they are hypothesized to be a causal factor in type 1 diabetes. The ...
A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a Coxsackievirus B1 vaccine Hankaniemi, Minna M.; Stone, Virginia M.; Sioofy-Khojine, Amir-Babak; Heinimäki, Suvi; Marjomäki, Varpu; Hyöty, Heikki; Blazevic, Vesna; Laitinen, Olli H.; Flodström-Tullberg, Malin; Hytönen, Vesa P. (Elsevier Ltd, 2019)Type B Coxsackieviruses (CVBs) belong to the enterovirus genus, and they cause both acute and chronic diseases in humans. CVB infections usually lead to flu-like symptoms but can also result in more serious diseases such ...
Formalin treatment increases the stability and immunogenicity of coxsackievirus B1 VLP vaccine Hankaniemi, Minna M.; Stone, Virginia M.; Andrejeff, Tanja; Heinimäki, Suvi; Sioofy-Khojine, Amir-Babak; Marjomäki, Varpu; Hyöty, Heikki; Blazevic, Vesna; Flodström-Tullberg, Malin; Hytönen, Vesa P.; Laitinen, Olli H. (Elsevier, 2019)Type B Coxsackieviruses (CVBs) are a common cause of acute and chronic myocarditis, dilated cardiomyopathy and aseptic meningitis. However, no CVB-vaccines are available for human use. We have previously produced virus-like ...
A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates Stone, V. M.; Hankaniemi, M. M.; Laitinen, O. H.; Sioofy-Khojine, A. B.; Lin, A.; Diaz Lozano, I. M.; Mazur, M. A.; Marjomäki, V.; Loré, K.; Hyöty, H.; Hytönen, V. P.; Flodström-Tullberg, M. (American Association for the Advancement of Science, 2020)Coxsackievirus B (CVB) enteroviruses are common human pathogens known to cause severe diseases including myocarditis, chronic dilated cardiomyopathy, and aseptic meningitis. CVBs are also hypothesized to be a causal factor ...